Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · EyePoint, Inc. (EYPT)

EyePoint's LUGANO Phase 3 trial misses primary endpoint for DURAVYU in wet AMD

Negative Impact 4 of 5 product/contract Written later

EyePoint posted an updated investor presentation on September 10, 2026, with preliminary topline results from the LUGANO Phase 3 wet AMD trial of DURAVYU. The filing states DURAVYU did not achieve statistical non-inferiority to on-label aflibercept in the full data set, a miss on the primary endpoint, and the company attributes the result mainly to 9 patients who lost 15 or more letters of vision from non-wet AMD causes.

Key points

  • Full data set: DURAVYU did not achieve statistical non-inferiority on mean change in BCVA versus on-label aflibercept (preliminary, pending final analysis).
  • Excluding the 9 of 211 DURAVYU patients in the asymmetric cohort, non-inferiority was achieved (nominal p=0.0096).
  • LUCIA Phase 3 data are expected in Q4 2026, and a wet AMD NDA filing is targeted for 1H 2027.
  • The presentation is filed as Exhibit 99.1 and is incorporated by reference; all LUGANO data are labeled preliminary.

The filing

CompanyEyePoint, Inc. (EYPT)
Form8-K, current report
Filed with the SECSep 10, 2026, 7:05 AM ET
Accession number0001193125-26-387197

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 10, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.